Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Contributed by: Business Wire

Logo

Business Wire logo

Tags

Biotechnology
Pharmaceutical
Health
Cardiology
Alnylam Pharmaceuticals, Inc.

More Like This

Business Wire logo

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Business Wire logo

Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024

Business Wire logo

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

Bayer receives MHRA authorisation for Beyonttra® ▼ (acoramidis) as a new treatment of transthyretin amyloidosis in adult patients with cardiomyopathy

Business Wire logo

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives

Business Wire logo

ENHERTU® Type II Variation Application Validated by EMA for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following At Least One Endocrine Therapy

PR Newswire associated0

European Commission Grants Orphan Drug Designation to Florbetaben (18F) for Diagnosis of ATTR Amyloidosis

Business Wire logo

TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2025

Terms of Use

Privacy Policy

Contact Us